Drug Profile
Hib-meningococcal vaccine groups A and C polysaccharide conjugate - Chongqing Zhifei Biological Products
Alternative Names: Hib-Group A and C meningococcal polysaccharide conjugate vaccine - Chongqing Zhifei Biological Products; HibACon - Chongqing Zhifei Biological Products; MenAC-Hib - Chongqing Zhifei Biological ProductsLatest Information Update: 06 Oct 2016
Price :
$50
*
At a glance
- Originator Chongqing Zhifei Biological Products
- Class Conjugate vaccines; Haemophilus vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilus infections; Meningococcal group A infections; Meningococcal group C infections
Most Recent Events
- 01 Aug 2016 Chongqing Zhifei Biological Products initiates a phase I/II trial in Haemophilus infections, Meningococcal group A infections and Meningococcal group C infections (Prevention, In infants) in China (IM) (NCT02919293)
- 05 Jun 2015 Phase III development is ongoing in China
- 30 Oct 2012 Phase-III clinical trials in Haemophilus infections (In children, In infants, Prevention) in China (IM)